Aspirin's effect on preventing recurrent acute pancreatitis

The Effect of 100mg Aspirin on Recurrent Acute Pancreatitis: a Prospective Cohort Study

This study is testing if taking 100mg of aspirin can help people who have had multiple episodes of acute pancreatitis avoid getting it again.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 23 (estimated)
• Ages: 14 Years to 80 Years
• Sex: All
• Sponsor: Air Force Military Medical University, China (other)
• Locations: 1 site (Xi'an, Shaanxi)
• Trial ID: NCT06185621 on ClinicalTrials.gov

What this trial studies

This study investigates the potential of 100mg aspirin to reduce the frequency of recurrent acute pancreatitis (RAP) in patients who have experienced multiple episodes of this condition. RAP is associated with significant morbidity and mortality, and current preventive measures are limited to specific causes. By exploring the anti-inflammatory properties of aspirin, the study aims to provide a new preventive strategy for patients with idiopathic RAP. The trial will include patients who meet specific criteria regarding their history of acute pancreatitis.

Who should consider this trial

Good fit: Ideal candidates for this study are patients who have experienced recurrent acute pancreatitis with at least two episodes in the past year.

Not a fit: Patients with less than two episodes of acute pancreatitis or those with iatrogenic pancreatitis will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could offer a new preventive treatment option for patients suffering from recurrent acute pancreatitis.

How similar studies have performed: While the use of NSAIDs for pancreatitis is a novel approach, there is limited existing research specifically on aspirin's effectiveness in preventing recurrent acute pancreatitis.

Eligibility criteria

Inclusion Criteria:

* Patients with with recurrent acute pancreatitis

Exclusion Criteria:

* Less than 2 episodes of acute pancreatitis in the past year
* Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis
* Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs)
* Regularly taking aspirin or other NSAIDs \>3 doses per week
* Contradictions for the medications of NSAIDs, including Active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100X10\^9/L or international normalized ratio (INR) \>1.5)
* Biliary stones
* Receiving endoscopic sphincterotomy and/or pancreatic stent placement and/or cholecystectomy and/or pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years
* Patients with the level of serum triglycerides of \>5.65 mmol/L and did not receive regular lipid-lowering therapy
* Primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \<2 years
* Patients with previously heavy alcohol consumption (50g/day for men, 40g/day for women) and have not quit drinking, or have significant withdrawal symptoms
* Pregnant or breastfeeding patients
* Inability to give informed consents

Where this trial is running

Xi'an, Shaanxi

• Air Force Military Medical University, China — Xi'an, Shaanxi, China (RECRUITING)

Study contacts

• Study coordinator: Yanglin Pan, MD

Conditions: Recurrent Acute Pancreatitis, Prevention, Aspirin